Related Experiment Video
Updated: Jun 14, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
DNA damage induced PARP-1 overactivation confers paclitaxel-induced neuropathic pain by regulating mitochondrial
Meng-Meng Ge1,2, Jun-Jie Hu3, Ya-Qun Zhou2
1Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Aims:
Poly (ADP-ribose) polymerase (PARP) has been extensively investigated in human cancers. Recent studies verified that current available PARP inhibitors (Olaparib or Veliparib) provided clinical palliation of clinical patients suffering from paclitaxel-induced neuropathic pain (PINP). However, the underlying mechanism of PARP overactivation in the development of PINP remains to be investigated.
Methods And Results:
We reported induction of DNA oxidative damage, PARP-1 overactivation, and subsequent nicotinamide adenine dinucleotide (NAD+) depletion as crucial events in the pathogenesis of PINP. Therefore, we developed an Olaparib PROTAC to achieve the efficient degradation of PARP. Continuous intrathecal injection of Olaparib PROTAC protected against PINP by inhibiting the activity of PARP-1 in rats. PARP-1, but not PARP-2, was shown to be a crucial enzyme in the development of PINP. Specific inhibition of PARP-1 enhanced mitochondrial redox metabolism partly by upregulating the expression and deacetylase activity of sirtuin-3 (SIRT3) in the dorsal root ganglions and spinal cord in the PINP rats. Moreover, an increase in the NAD+ level was found to be a crucial mechanism by which PARP-1 inhibition enhanced SIRT3 activity.
Conclusion:
The findings provide a novel insight into the mechanism of DNA oxidative damage in the development of PINP and implicate PARP-1 as a possible therapeutic target for clinical PINP treatment.
Insights
Poly (ADP-ribose) polymerase-1 (PARP-1) overactivation drives paclitaxel-induced neuropathic pain (PINP) via oxidative damage. Inhibiting PARP-1 with a novel PROTAC therapy offers a promising treatment strategy for PINP.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in managing paclitaxel-induced neuropathic pain (PINP).
- The precise mechanisms underlying PARP overactivation in PINP pathogenesis require further elucidation.
Purpose of the Study:
- To investigate the role of PARP overactivation in PINP development.
- To explore the therapeutic potential of targeting PARP-1 for PINP treatment.
Main Methods:
- Investigated DNA oxidative damage, PARP-1 overactivation, and nicotinamide adenine dinucleotide (NAD+) depletion in PINP.
- Developed and administered an Olaparib PROTAC via intrathecal injection in a rat model.
- Assessed the impact of PARP-1 inhibition on mitochondrial redox metabolism and sirtuin-3 (SIRT3) activity.
Main Results:
- PARP-1 overactivation and NAD+ depletion are key events in PINP pathogenesis.
- Olaparib PROTAC treatment effectively inhibited PARP-1 and protected against PINP in rats.
- PARP-1 inhibition upregulated mitochondrial redox metabolism and SIRT3 activity, linked to increased NAD+ levels.
Conclusions:
- Findings reveal DNA oxidative damage as a mechanism in PINP.
- PARP-1 is identified as a critical therapeutic target for managing PINP.
Related Concept Videos
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Abnormal Proliferation
Long-patch Base Excision Repair
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

